Vmax™ Express Electrocompetent Cells QRM for Experienced Users

Total Page:16

File Type:pdf, Size:1020Kb

Vmax™ Express Electrocompetent Cells QRM for Experienced Users Vmax™ Express Electrocompetent Cells Quick Reference Manual for Experienced Users Catalog Numbers CL1100-05, CL1100-10, CL1100-20 For complete product information and a detailed protocol visit sgidna.com/vmax-express. Vmax™ Express Electrocompetent Cells Contents Cat. No. CL1100-05 Cat. No. CL1100-10 Cat. No. CL1100-20 Storage Component (5 Reactions) (10 Reactions) (20 Reactions) Temperature* Quantity Vmax™ Express 5 vials 10 vials 20 vials −80°C Electrocompetent Cells Vmax™ Recovery Medium 5 vials 10 vials 20 vials 4°C (after opening) Positive control 1 vial 1 vial 1 vial −20°C pACYC/Chlor plasmid *All components are shipped on dry ice and may be stored at −80°C if desired. Unopened vials of Vmax™ Recovery Medium can be stored at room temperature (20 to 24°C). Vmax™ Express handling practices 6. Transfer cells to a chilled cuvette using a pipette. • Use cells within 6 months of receipt. 7. Transfer the cuvette to the shock pod and perform • Protect cells from temperature fluctuations during electroporation. storage. Note: Time constants typically range from 3.3–3.7 ms. • Thaw cells on ice just prior to use. 8. Transfer cells to a room temperature Falcon® 14-mL • Gently flick tubes to mix or resuspend. Round-Bottom Tube containing recovery media • Pre-warm media before use. immediately after pulse. • After transformation, recover cells for a full 2 hours in 9. To transfer any remaining cells, add 200 μL of Vmax™ the provided Vmax™ Recovery Medium before plating. Recovery Media to the cuvette. Dispense the media to • Store agar plates with Vmax™ Express cells at room the same round-bottom tube from Step 8. temperature. Do not store agar plates at 2°C to 8°C. 10. Place the Falcon® 14-mL Round-Bottom Tubes in a • Agar plates may be left at room temperature for up to tube rack in an orbital shaker (250 rpm) at 30°C or 37°C 72 hours. for 2 hours. • For long-term storage, we recommend preparing 11. During cell recovery, pre-warm LB-Miller agar plates glycerol stocks with 25% glycerol and storing at −80°C. prepared with antibiotics at an appropriate incubation temperature. Electroporation protocol 1. For each transformation reaction, Plating instructions • Thaw one vial of Vmax™ Express 1. Add 50 μL (for vectors isolated from Vmax™ Electrocompetent cells on ice for 5 minutes. cells) or 200 μL (for E. coli-derived vectors) of the • Warm one vial of Vmax™ Recovery Media to room transformation reaction to the center of an LB- temperature (20°C to 24°C). Miller plate. Use a sterile spreader or sterile beads to • Pre-chill a 0.1-cm electroporation cuvette on ice. distribute cells across the surface of the plate. 2. Transfer 500 μL Vmax™ Recovery Media to a Falcon® 2. (Optional) For the control plasmid, dilute the 14-mL Round-Bottom Tube. transformation reaction 1:200 with Vmax™ Recovery 3. As soon as the electrocompetent cells are thawed, add Medium. Plate 50–100 μL of the diluted reaction on an 1–100 ng (2 μL maximum volume) of plasmid DNA (in LB-Miller agar plate supplemented with 5–12.5 μg/mL TE buffer or water only) to the competent cells on ice. chloramphenicol. Briefly mix by flicking tubes. 3. Incubate plates at 25°C, 30°C, or 37°C for at least 4. Incubate the DNA and cell mixture on ice for 8 hours. 3–5 minutes. Note: For kanamycin plates, incubate at 25°C to 30°C. 5. Set the Gene Pulser® Xcell™ System to the following Do not incubate kanamycin plates at 37°C. electroporation parameters: 900 V, 25 uF, 200 Ohms, 0.1-cm cuvette. Note: Use of an electroporator other than the Gene Pulser® Xcell™ System may require optimization of electroporation conditions. Synthetic Genomics, Inc. syntheticgenomics.com Preparing seed cultures Maintaining antibiotic selection 1. Pick the first/largest colonies to appear. Recommended concentrations for maintaining antibiotic 2. Inoculate a culture tube containing 2–15 mL growth selection using Vmax™ Express culture on solid or liquid media supplemented with appropriate antibiotics at culture are listed in the following table. room temperature, 30°C, or 37°C. Solid media Liquid culture Antibiotic marker 3. Culture cells at 30°C or 37°C at 250 rpm according to the Concentration guidelines in the following table. Ampicillin 10–50 μg/mL 50–100 μg/mL Rapid expression Standard Carbenicillin 2–25 μg/mL 5–100 μg/mL protocol protocol Kanamycin 100 μg/mL 200 μg/mL ~3 hours Incubation duration 6–16 hours (for 25 mL of medium) Tetracycline 2.5 μg/mL 2.5 μg/mL Chloramphenicol 5–12.5 μg/mL 12.5–25 μg/mL OD600 post-incubation ≥0.3 2–7 Seed stock use medium-scale large-scale For glycerol stocks? No Yes Recipes For optimal cell growth in liquid cultures, Vmax™ Enriched Glycerol stocks Growth Medium (SGI-DNA Cat. No. CL1500-1000) is recommended for best results. Alternatively, the following 1. Add 250 μL of sterile 100% glycerol to a 1-mL liquid media can be used. For best results use a growth cryopreservation vial or other −80°C compatible sterile media listed here. Other liquid media can result in poor tube. Add 750 μL of bacterial seed culture (prepared as growth and/or expression. described above) and mix for a final concentration of 25% glycerol. Liquid culture Enhanced 2xYT medium 2. Place vials in –80°C freezer for storage. 20 g/L Yeast Extract 3. To recover culture, use a sterile inoculation loop to 32 g/L Tryptone scoop frozen culture and transfer to liquid or solid 17 g/L NaCl growth medium with appropriate antibiotics and supplemented with 0.2% Glucose and 17.6 mM Na2HPO4 incubate at room temperature, 30°C, or 37°C. adjusted to pH 7.4 Note: Always incubate kanamycin-resistant strains Brain heart infusion broth + v2 salts grown on solid agar medium at 30°C or room 37 g/L Brain Heart Infusion Broth Dry Media temperature. (Teknova Cat. No. B9500) supplemented with additional salts: 204.0 mM NaCl Protein expression protocol 4.2 mM KCl 23.14 mM MgCl2 1. Inoculate a seed culture (OD600 of 2–7 for standard protocol, >0.3 for rapid protocol) into growth medium For optimal cell growth on agar plates, we recommend containing appropriate antibiotics. Use 1/100 volume of LB-Miller agar: seed culture relative to the total amount of medium. Solid media 2. Grow culture at 30°C for ~1–2 hours on a rotating shaker LB-Miller agar incubator at 250 rpm until the OD600 reaches >0.5. 10 g/L Tryptone 5 g/L Yeast Extract 3. After reaching OD600 of ≥0.5, induce protein expression by adding IPTG to a final concentration of 1 mM. 10 g/L NaCl 1.5% agar 4. Incubate induced cells for 4–24 hours. 5. Harvest cells by transferring to a centrifugation tube and spinning at 4000–5000 × g for 10 minutes at room temperature or 4°C. Carefully remove supernatant. 6. Store the cell pellet at −80°C or proceed to lysis and protein purification. Complete product information and additional resources are available at sgidna.com/vmax-express. Technical Services [email protected] Trademarks Synthetic Genomics® is a registered trademark and Vmax™ is a trademark of Synthetic Genomics Inc. Gene Pulser® is a registered trademark and Xcell™ is a trademark of Bio-Rad Laboratories, Inc. Falcon® is a registered trademark of Corning Inc. Disclaimer The material in this manual is for informational purposes only and is subject to change without prior notice at any time. Synthetic Genomics and/or its affiliates assume no responsibility for any errors that may appear in this document. Label License Research Vmax™ Express Electrocompetent Cells (Catalog Numbers CL1100-05, CL1100-10, CL1100-20), and components and products thereof, are to be used for Use Only research purposes for the sole benefit of the purchaser only. These cells are sold only for the intended purpose of recombinant protein expression for research purposes. They may not be used for any other purpose, including, but not limited to, use in drugs, diagnostics, therapeutics or in humans. The above mentioned products and components and products thereof, may not be reverse engineered, remade, transferred or sold to third parties, resold, modified for resale, or used to manufacture commercial products or provide commercial services. Except as otherwise agreed in writing by our authorized representative, this product is for INTERNAL RESEARCH USE ONLY AND NOT FOR HUMAN, ANIMAL, THERAPEUTIC OR DIAGNOSTIC USE. For additional information about your rights under this research license, please see our General Terms of Service (located at customer.sgidna.com/TOS.pdf). For information on obtaining additional rights, please contact Synthetic Genomics® at [email protected]. © 2018 Synthetic Genomics Inc. All rights reserved. Part Number 40031 Synthetic Genomics, Inc. REV 1.0 06.08.18.
Recommended publications
  • PA00XCSB.Pdf
    Leidos Proprietary 1. EXECUTIVE SUMMARY A summary of efforts for the planned, ongoing, and completed projects for the Malaria Vaccine Development Program (MVDP) contract for this reporting period are herein detailed. A compiled Gantt chart including activities associated with each of the projects has been created and included as an attachment to this report. Ongoing projects that will continue through FY2019 include two vaccine development projects, the CSP vaccine development project (CSP Vaccine) and liver stage vaccine development project (Liver Stage Vaccine), as well as the clinical study with RH5 (RH5.1 Clinical Study), the latter to assess long-term immunogenicity in RH5.1/AS01 vaccinees. Of note is that while both the CSP and the liver stage vaccine development projects were initiated as epitope-based projects, these have since been realigned to target whole proteins; therefore, the project names have also been realigned to remove “epitope-based.” Expansion of work on the RCR complex into a vaccine development project (RCR Complex) occurred in early FY2019 and this project will continue until the end date of the contract. Lastly, a new project, the RH5.1 human monoclonal antibody identification and development project (RH5.1 Human mAb), was initiated in early FY2019 and will continue until the end date of the contract. Two projects were completed in FY2019, the blood stage epitope-based vaccine development project and the PD1 blockade inhibitor project (PD1 Block Inh). Leidos continues to seek collaborators for information exchange under NDA, reagent exchange under MTA, and collaboration under CRADA, to expand our body of knowledge and access to reagents with minimal cost to the program.
    [Show full text]
  • Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
    Send Orders of Reprints at [email protected] Current Genomics, 2013, 14, 11-24 11 Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns 1,2, 1 1 1 Harald König *, Daniel Frank , Reinhard Heil and Christopher Coenen 1Institute for Technology Assessment and Systems Analysis (ITAS); 2Institute of Toxicology and Genetics (ITG), Karlsruhe Institute of Technology, PO box 3640, 76021 Karlsruhe, Germany Abstract: New organisms and biological systems designed to satisfy human needs are among the aims of synthetic ge- nomics and synthetic biology. Synthetic biology seeks to model and construct biological components, functions and or- ganisms that do not exist in nature or to redesign existing biological systems to perform new functions. Synthetic genom- ics, on the other hand, encompasses technologies for the generation of chemically-synthesized whole genomes or larger parts of genomes, allowing to simultaneously engineer a myriad of changes to the genetic material of organisms. Engi- neering complex functions or new organisms in synthetic biology are thus progressively becoming dependent on and con- verging with synthetic genomics. While applications from both areas have been predicted to offer great benefits by mak- ing possible new drugs, renewable chemicals or clean energy, they have also given rise to concerns about new safety, en- vironmental and socio-economic risks – stirring an increasingly polarizing debate. Here we intend to provide an overview on recent progress in biomedical and biotechnological applications of synthetic genomics and synthetic biology as well as on arguments and evidence related to their possible benefits, risks and governance implications. Received on: May 22, 2012- Revised on: October 11, 2012- Accepted on: October 12, 2012 Keywords: Applications, Benefits, Biofuels, Biomedicine, Environment, Risks, Synthetic genomics, Synthetic biology.
    [Show full text]
  • Commissioned Papers Synthetic Genomics: Risks and Benefits For
    Commissioned Papers Synthetic Genomics: Risks and Benefits for Science and Society This volume of papers accompanies the report Synthetic Genomics: Options for Governance Synthetic Genomics: Risks and Benefits for Science and Society (this page blank) Synthetic Genomics: Risks and Benefits for Science and Society COMMISSIONED PAPERS TABLE OF CONTENTS Robert Jones Sequence Screening……………………………………………………………...……1-16 Yogesh Sanghvi A Roadmap to the Assembly of Synthetic DNA from Raw Materials……..………….17-33 Ralph S. Baric Synthetic Viral Genomics…………………………………………………………….35-81 Marc S. Collett Impact of Synthetic Genomics on the Threat of Bioterrorism with Viral Agents..………………………………………………………………………..83-103 Diane O. Fleming Risk Assessment of Synthetic Genomics: A Biosafety and Biosecurity Perspective………………………...………………………………….105-164 Franco Furger From Genetically Modified Organisms to Synthetic Biology: Legislation in the European Union, in Six Member Countries, and in Switzerland…………………………………………………………..……..165-184 Synthetic Genomics: Risks and Benefits for Science and Society (this page blank) Synthetic Genomics: Risks and Benefits for Science and Society The following papers were commissioned for the project Synthetic Genomics: Risks and Benefits for Science and Society. These papers formed the basis of many discussions at project workshops and at a large invitational meeting. The information elicited from these meetings, and from the commissioned papers themselves, formed the basis of our report Synthetic Genomics: Options for Governance (http://dspace.mit.edu/handle/1721.1/39141). The views and opinions expressed in these commissioned papers are those of the authors of the papers and not necessarily those of the authors of the report, or of the institutions at which the authors work. Citation: Working Papers for Synthetic Genomics: Risks and Benefits for Science and Society.
    [Show full text]
  • Xenobiology: a New Form of Life As the Ultimate Biosafety Tool Markus Schmidt* Organisation for International Dialogue and Conflict Management, Kaiserstr
    Review article DOI 10.1002/bies.200900147 Xenobiology: A new form of life as the ultimate biosafety tool Markus Schmidt* Organisation for International Dialogue and Conflict Management, Kaiserstr. 50/6, 1070 Vienna, Austria Synthetic biologists try to engineer useful biological search for alternatives. They belong to apparently very systems that do not exist in nature. One of their goals different science fields and their quest for biochemical is to design an orthogonal chromosome different from diversity is driven by different motivations.(1–3) The science DNA and RNA, termed XNA for xeno nucleic acids. XNA exhibits a variety of structural chemical changes relative fields in question include four areas: origin of life, exobiology, to its natural counterparts. These changes make this systems chemistry, and synthetic biology (SB). The ancient novel information-storing biopolymer ‘‘invisible’’ to nat- Greeks, including Aristotle, believed in Generatio spontanea, ural biological systems. The lack of cognition to the the idea that life could suddenly come into being from non- natural world, however, is seen as an opportunity to living matter on an every day basis. Spontaneous generation implement a genetic firewall that impedes exchange of genetic information with the natural world, which means of life, however, was finally discarded by the scientific it could be the ultimate biosafety tool. Here I discuss, why experiments of Pasteur, whose empirical results showed that it is necessary to go ahead designing xenobiological modern organisms do not spontaneously arise in nature from systems like XNA and its XNA binding proteins; what non-living matter. On the sterile earth 4 billion years ago, the biosafety specifications should look like for this however, abiogenesis must have happened at least once, genetic enclave; which steps should be carried out to boot up the first XNA life form; and what it means for the eventually leading to the last universal common ancestor society at large.
    [Show full text]
  • IGF-II) Gene in Villus During 610 Gestational Weeks, Jianhong Chen, Qun Fang, Baojiang Chen, Yi Zhou, and Yanmin Luo Volume 2010, Article ID 965905, 4 Pages
    Obstetrics and Gynecology International Epigenetic Regulation in Reproductive Medicine and Gynecologic Cancers Guest Editors: Shi-Wen Jiang, Brian Brost, Sean Dowdy, Xing Xie, and Fan Jin Epigenetic Regulation in Reproductive Medicine and Gynecologic Cancers Obstetrics and Gynecology International Epigenetic Regulation in Reproductive Medicine and Gynecologic Cancers Guest Editors: Shi-Wen Jiang, Brian Brost, Sean Dowdy, Xing Xie, and Fan Jin Copyright © 2010 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in volume 2010 of “Obstetrics and Gynecology International.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Obstetrics and Gynecology International Editorial Board Sean Blackwell, USA Howard D. Homesley, USA Faustino R. Perez-L´ opez,´ Spain Diane C. Bodurka, USA Shi-Wen Jiang, USA Tonse N.K. Raju, USA Curt W. Burger, The Netherlands Marc J. N. C. Keirse, Australia Neal S. Rote, USA Linda D. Cardozo, UK Russell K. Laros Jr., USA Giovanni Scambia, Italy Nancy Chescheir, USA Jonathan Ledermann, UK Peter E. Schwartz, USA Robert Coleman, USA Kimberly K. Leslie, USA John J. Sciarra, USA W. T. Creasman, USA Lawrence D. Longo, USA J. L. Simpson, USA Mary E. D’Alton, USA G. A. Macones, USA Anil Sood, USA Gian Carlo Di Renzo, Italy Everett Magann, USA Wiebren A. A. Tjalma, Belgium Keith A. Eddleman, USA James A. McGregor, USA J. R. Van Nagell, USA Edmund F. Funai, USA Liselotte Mettler, Germany John M. G. van Vugt, The Netherlands Norbert Gleicher, USA Daniel R.
    [Show full text]
  • SGI-DNA-Bioxp-Lucigen-Webinar
    Accelerate your Research with Synthetic DNA and Hands-free Cloning Brought to you in collaboration with Lucigen and SGI-DNA Introduction Julie K. Robinson Synthetic Genomics, SGI-DNA Sr. Product Manager, Synthetic Biology The Potential of Synthetic Biology C O P Y R I G H T © 2 0 1 7 S Y N T H E T I C G E N O M I C S , I N C. | 2 Synthetic Genomics Collaborative Efforts Advance C O P Y R I G H T © 2 0 1 7 S Y N T H E T I C G E N O M I C S , I N C. | 3 Advancing Genomic Research Solutions, SGI-DNA Reagents Instruments ● Gibson Assembly® enables rapid assembly ● BioXp™ 3200 – an automated, benchtop of multiple DNA fragments genomics workstation ● Vmax electrocompetent cells for protein ● Create genes, genetic elements and complex expression genetic sequences ● Uses electronically transmitted sequence to build genes Services Bioinformatics ● Synthesize custom DNA of varying size ● Expert bioinformatics support, which and complexity includes whole genome annotation, gene expression analysis, and other types of ● Utilizes patented Gibson Assembly® sequence design method and error correction technology ● Archetype® software enables ‘omics-based ● Cell engineering services understanding of data to enable researchers ● NGS and plasmid preparation services to discover, analyze and build genes C O P Y R I G H T © 2 0 1 7 S Y N T H E T I C G E N O M I C S , I N C. | 4 Common Genomic applications Applications of DNA Cloning Study of Genomes & Transgenic Gene Expression Gene Therapy Organisms Biopharmaceutical Recombinant Protein Cell Engineering Research Production C O P Y R I G H T © 2 0 1 7 S Y N T H E T I C G E N O M I C S , I N C.
    [Show full text]
  • Prospect of Human Age Reversal Page 10
    A Non-Profit Organization NOvember - DecemberJanuary 20152017 • VoVolumelume 36:138:6 Prospect of Human Age Reversal Page 10 Member Profile: Christine Peterson Page 16 ISSN 1054-4305 Brain Preservation and Personal Survival $9.95 Page 20 Improve Your Odds of a Good Cryopreservation You have your cryonics funding and contracts in place but have you considered other steps you can take to prevent problems down the road? ü Keep Alcor up-to-date about personal and medical changes. ü Update your Alcor paperwork to reflect your current wishes. ü Execute a cryonics-friendly Living Will and Durable Power of Attorney for Health Care. ü Wear your bracelet and talk to your friends and family about your desire to be cryopreserved. ü Ask your relatives to sign Affidavits stating that they will not interfere with your cryopreservation. ü Attend local cryonics meetings or start a local group yourself. ü Contribute to Alcor’s operations and research. Contact Alcor (1-877-462-5267) and let us know how we can assist you. Visit the ALCOR FORUMS www.alcor.org/forums/ Discuss Alcor and cryonics topics with other members and Alcor officials. • The Alcor Foundation • Financial • Cell Repair Technologies • Rejuvenation • Cryobiology • Stabilization • Events and Meetings Other features include pseudonyms (pending verification of membership status) and a private forum. Visit the ALCOR BLOG www.alcor.org/blog/ Your source for news about: • Cryonics technology • Speaking events and meetings • Cryopreservation cases • Employment opportunities • Television programs about cryonics Alcor is on Facebook Connect with Alcor members and supporters on our official Facebook page: www.facebook.com/alcor.life.extension.foundation Become a fan and encourage interested friends, family members, and colleagues to support us too.
    [Show full text]
  • Venter – Synthetic Genomics
    NSABB July 1, 2005 Synthetic Genomics From Reading to Writing the Genetic Code Genes are the design components of the future Ten years ago this month Microbial Abundance . Microbes make up roughly ½ of the Earth’s biomass . 6 x 1030 microbes over entire Earth . Animals make up 1/1000th of Earth’s total biomass . Each ml of sea water has one million bacteria and 10 million viruses www.sorcerer2expedition.org Sorcerer II Global Ocean Survey: Nova Scotia through Galapagos Islands Sargasso Sea Pilot Study 100 Million letters of genetic code every 24 hours 454 Genome Sequencing System . Up to 100x throughput over Fluorescent Sequencing: - 20 megabases/4 hr instrument run (20-32 high Q) Current vs 454 Platform 3730 454 Bases per day 945K 100-200 million Runs per day 12 5 Bases per run 78.7K 20-40 million Average RL 820bp 125bp Cost ~$0.0012/base $0.00025/base ( $1.20/Kb) ($0.25/Kb) Marine Microbe Sequencing Project . $9M Funded by Gordon and Betty Moore Foundation Sequence, Assemble and Auto-Annotate up to 130 Marine Microbes Add to the current (10-20) set of sequenced Marine Microbes - 1000% increase Synergy with Sorcerer Expedition Sorcerer II Expedition and Moore Foundation Isolated Organisms 1 4 11 1 4 1 2 3 Canada 8 1 7 1 1 1 12 4 2 2 1 Bermuda Mexico 3 1 1 1 2 Honduras1 Panama 2 2 1 Cocos Islands 1 1 French 2 Galapagos Tonga Polynesia Islands Vanuatu 1 Fiji Cook New Islands 1Caledonia Australia 1 1 1 1 Sampled stations Planned stations Number of organisms isolated from each region for the Moore Foundation Program Aerosol sample collection .
    [Show full text]
  • PDF: the Future Is History
    .horizons The Future is History Jeremy Geelen, PhD and Monica Harvey1 Institute for Science, Society and Policy to essential medicines a thing of the past. Already in The future has arrived - and it’s here to stay 2008, researchers at the University of California turned a yeast cell into an anti-malaria medicine factory, producing medicine much cheaper and faster than the usual method of extracting the drug from wormwood plants (Interlandi, 2008). The same researchers have also reprogrammed E. coli bacteria to produce medicines such as taxol, an anticancer drug, and prostratin, a potential anti-HIV drug (Bower, 2005). And synthetic biology offers the prospect of producing better drugs. Herceptin, for example, has been found to reduce the reoccurrence of breast cancer, significantly improving chances of survival (Komarova et al., 2011). Technologies that only a few years ago were fodder for futurists are now a reality. They hold the promise Potential Policy Implications of profound advancements in medicine, economic development and environmental stewardship. But they While the potential benefits of synthetic biology are may also bring significant policy challenges. remarkable, the technology could also be used to produce personalized bioweapons and reprogrammed This brief highlights 10 of today’s most cutting-edge super-viruses that could pose grave threats to human technological advancements and outlines potential health. policy implications. The standardization of methods and DNA parts has allowed synthetic biology methods to become simple Faster, Cheaper Medicine through Synthetic and relatively easy to recreate, allowing anyone to alter 1 Biology and manipulate biology for good or ill. “The lack of access to essential medicines in developing countries is one of the most pressing global health Organs-on-demand with 3D Printing issues.
    [Show full text]
  • Synthetic Biology. Latest Developments, Biosafety
    Synthetic Biology Latest developments, biosafety considerations and regulatory challenges DO Expertise, Service provision and Customer relations Biosafety and Biotechnology Unit Rue Juliette Wytsmanstraat 14 1050 Brussels | Belgium www. wiv-isp.be Biosafety and Biotechnology Unit | September 2012 | Brussels, Belgium Responsible Editor : Dr Johan Peeters, General Director Nr Deposit: D/2012/2505/46 Email: [email protected] Picture cover page: Strains of Escherichia coli have been developed to produce lycopene, an antioxidant found in tomatoes. Source: (Baker 2011). Authors : Katia Pauwels Nicolas Willemarck Didier Breyer Philippe Herman D/2012/2505/46 - p. 2 - SUMMARY Synthetic Biology (SB) is a multidisciplinary and rapidly evolving field. It can be summarized as the rational design and construction of new biological parts, devices and systems with predictable and reliable functional behavior that do not exist in nature, and the re-design of existing, natural biological systems for basic research and useful purposes. Four major SB approaches have been distinguished in this document: (i) Engineering DNA-based biological circuits; (ii) Defining a minimal genome/minimal life (top-down approach); (iii) Constructing protocells or synthetic cells from scratch (bottom-up approach); and (iv) Developing orthogonal biological systems (Xenobiology). There is currently no internationally agreed consensus about a definition of synthetic biology. Although having such a definition could facilitate enabling a rational discussion of this issue, we do not see the adoption of a definition as key for discussing the potential regulatory and risk assessment challenges of SB. It is expected that on the short term activities in SB will focus on research and development or on commercial production of substances in contained facilities.
    [Show full text]
  • AN EXAMINATION of CONTINGENCY in SYNTHETIC GENOMICS RESEARCH and IMPLICATIONS for NATIONAL SECURITY By
    AN EXAMINATION OF CONTINGENCY IN SYNTHETIC GENOMICS RESEARCH AND IMPLICATIONS FOR NATIONAL SECURITY by Shannon R. Fye-Marnien A Dissertation Submitted to the Graduate Faculty of George Mason University in Partial Fulfillment of The Requirements for the Degree of Doctor of Philosophy Biodefense Committee: Sonia Ben Ouagrham-Gormley, Chair Serguei Popov A. Trevor Thrall Kathleen M. Vogel Gregory Koblentz, Program Director Mark J. Rozell, Dean Date: Fall Semester 2015 George Mason University Fairfax, VA An Examination of Contingency in Synthetic Genomics Research and Implications for National Security A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at George Mason University by Shannon R. Fye-Marnien Master of Science George Mason University, 2006 Bachelor of Science California State University, Sacramento, 2004 Director: Sonia Ben Ouagrham-Gormley, Chair, Professor Biodefense Program Fall Semester 2015 George Mason University Fairfax, VA Copyright 2015 Shannon R. Fye-Marnien All Rights Reserved ii DEDICATION This dissertation is dedicated to my beloved grandmother, Roberta Corbett Huffman, who is greatly missed. iii ACKNOWLEDGEMENTS This dissertation is the result of the encouragement and insight of many people. First and foremost, I would like to thank my committee members, Sonia Ben Ouagrham- Gormley, Kathleen Vogel, Serguei Popov, and Trevor Thrall, for providing input that has improved this project immensely. I am deeply honored to have worked with each of them. Thanks especially to my committee chair, Sonia Ben Ouagrham-Gormley, for her guidance and for helping me publish some of my research findings in a peer-reviewed journal (Sonia Ben Ouagrham-Gormley and Shannon R.
    [Show full text]
  • SYNTHETIC GENOMICS | Options for Governance
    SYNTHETIC GENOMICS | Options for Governance Michele S. Garfinkel, The J. Craig Venter Institute, Rockville, Maryland, Drew Endy, Massachusetts Institute of Technology, Cambridge, Massachusetts, Gerald L. Epstein, Center for Strategic and International Studies, Washington, District of Columbia and Robert M. Friedman, The J. Craig Venter Institute, Rockville, Maryland October 2007 The views and opinions expressed in this report are those of the authors and not necessarily those of the other study Core Group members, the participants of the workshops discussed in this report, or of the institutions at which the authors work. The authors assume full responsibility for the report and the accuracy of its contents. We gratefully acknowledge the Alfred P. Sloan Foundation for support of this study. EXECUTIVE SUMMARY Summary Table of Options Gene Firms Oligo Manufacturers DNA Synthesizers Users and Organizations Does the Option: II-2. Ownersmust be of licensed DNAI1-3. synthesizers Licensingrequired ofto equipment,buyIII-1. reagents Educationpractices plus and inlicenseabout servicesuniversityIII-2. risks Compilein and curriculaSynthetic best a manualIII-3. Biology Establish bestfor Laboratories” “Biosafety practices a clearinghouseIII-4. Broadenresponsibilities for IBC reviewIII-5. Broadenoversight IBC by III-6.Nationalreview, Broadenenhanced plus Advisory IBC enforcement review, plus Enhance Biosecurity IA-1. ordersGene rms mustIA-2. screen Biosafetypeople who ofcers IA-3.place must Hybrid: biosafetyorders certify Firms ofcerIA-4. must must aboutFirms
    [Show full text]